Herniorrhaphy Study for Opioid Elimination

PHASE3CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

October 25, 2021

Study Completion Date

November 22, 2021

Conditions
Analgesia
Interventions
DRUG

HTX-011

300 mg

DEVICE

Luer lock applicator

Applicator for instillation

DRUG

Ibuprofen

600 mg

DRUG

Acetaminophen

1 g

Trial Locations (30)

10461

Montefiore Hutchinson Campus, The Bronx

11794

Stony Brook University Hospital, Stony Brook

15232

UPMC Shadyside Hospital, Pittsburgh

15237

UPMC Passavant, Pittsburgh

19104

Penn Presbyterian Medical Center, Philadelphia

19107

Thomas Jefferson University Hospital, Philadelphia

27704

M3 Emerging Medical Research, LLC, Durham

33144

Medical Research of Westchester, Inc, Miami

33713

Professional Health Care of Pinellas, St. Petersburg

40202

University of Louisville Hospital, Louisville

43210

The Ohio State University Wexner Medical Center - University Hospital, Columbus

44111

Cleveland Clinic Fairview, Cleveland

44195

Cleveland Clinic, Cleveland

45417

Midwest Clinical Research Center, LLC, Dayton

63110

Washington University School of Medicine, St Louis

75093

Plano Surgical Hospital, Plano

75246

Baylor University Medical Center, Dallas

Baylor University Medical Center, Dallas

77004

Hermann Drive Surgical Hospital, Houston

77030

Houston Methodist Hospital, Houston

78229

Endeavor Clinical Trials, LLC, San Antonio

84020

JBR Clinical Research, Draper

91942

Horizon Clinical Research, La Mesa

Sharp Grossmont Hospital, La Mesa

92503

Parkview Community Hospital, Riverside

92801

Anaheim Clinical Trials, LLC, Anaheim

92868

University of California, Irvine Medical Center, Orange

97701

Summit Medical Group Oregon-Bend Memorial Clinic, Bend

06510

Yale University School of Medicine, New Haven

07103

Rutgers - New Jersey Medical School, Newark

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Heron Therapeutics

INDUSTRY